Back to Journals » Cancer Management and Research » Volume 12

Percutaneous Endoscopic Gastrostomy Tube Placement in Patients with Head and Neck Cancer Treated with Radiotherapy

Authors Lang K, ElShafie RA, Akbaba S, Koschny R, Bougatf N, Bernhardt D, Welte SE, Adeberg S, Häfner M, Kargus S, Plinkert PK, Debus J, Rieken S

Received 25 June 2019

Accepted for publication 2 December 2019

Published 8 January 2020 Volume 2020:12 Pages 127—136

DOI https://doi.org/10.2147/CMAR.S218432

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo


Kristin Lang, 1– 3 Rami A ElShafie, 1– 3 Sati Akbaba, 1– 3 Ronald Koschny, 4 Nina Bougatf, 1– 3, 5 Denise Bernhardt, 1– 3, 5 Stefan E Welte, 1– 3, 5 Sebastian Adeberg, 1– 3, 5 Matthias Häfner, 1– 3, 5 Steffen Kargus, 6 Peter K Plinkert, 7 Jürgen Debus, 1– 3, 5, 8 Stefan Rieken 1– 3, 5, 8 

1Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg 69120, Germany; 2Heidelberg Institute of Radiation Oncology (HIRO), University Hospital of Heidelberg, Heidelberg 69120, Germany; 3National Center for Tumor Diseases (NCT), University Hospital of Heidelberg, Heidelberg, Germany; 4Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany; 5Heidelberg Ion Therapy Center (HIT), University Hospital of Heidelberg, Heidelberg 69120, Germany; 6Department of Oral and Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg 69120, Germany; 7Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany; 8Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany

Correspondence: Kristin Lang
Department of Radiation Oncology, University of Heidelberg, Im Neuenheimer Feld 400, Heidelberg 69120, Germany
Tel +49-6221-56-8202
Fax +49-6221-56-5353
Email Kristin.Lang@med.uni-heidelberg.de

Background and aim: The primary aim of our study was to evaluate percutaneous endoscopic gastrostomy (PEG) tube placement depending on body weight and body mass index in patients undergoing radiotherapy (RT) for head and neck cancer (HNC). A secondary aim was to evaluate the course of weight change following PEG placement.
Methods: We retrospectively reviewed the medical records of 186 patients with HNC undergoing radiotherapy (RT) or chemoradiotherapy (CRT) at our institution between January 2010 and August 2017. Initial weight and nutritional intake were analyzed prior to RT initiation and then followed throughout treatment until completion. Based on these data, the indication of PEG placement was determined. Medical records were also reviewed to analyze PEG-related acute toxicities.
Results: A total of 186 patients met inclusion criteria. Patients were most commonly male (n=123, 66.1%) with squamous cell carcinoma (n=164, 88.2%). Patients who had dysphagia prior to treatment initiation as well as patients with a BMI 2 needed PEG placement earlier during the treatment course. Low-grade toxicities related to PEG insertion were observed in 10.7% patients, with peristomal pain and redness adjacent to the PEG tube insertion site being most common. High-grade toxicities, such as peritonitis and organ injury, were found in 4.9% of patients.
Conclusion: Underweight patients and those with preexisting dysphagia should be closely screened during RT for weight loss and decreased oral intake. For weight loss greater than 4.5% during the treatment of HNC, early PEG-tube placement should be considered. Further prospective studies are needed to confirm these findings, and delineate a scoring system for timing of PEG use (prophylactic vs reactive) as well as assess the quality of life in patients with HNC who receive PEG placement.

Keywords: head and neck cancer, radiotherapy, PEG placement, body mass index, toxicity


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]